23% of Online Peptide Supplements Mislabeled: 2023 FDA Survey

In 2023, analytical chemistry groups at two US universities collaborated on an independent survey of peptide-containing products purchased through online channels—including dietary supplement retailers, research-chemical vendors, and direct-from-manufacturer websites. The survey tested 90+ products using HPLC coupled to mass spectrometry, measuring both qualitative identity (is the labeled peptide actually present?) and quantitative content (does the measured amount match the label claim within a defined tolerance?) [1].

The headline finding, subsequently cited in FDA public communications and consumer-protection advisories, was that 23% of sampled products failed one or more of these criteria. Failures clustered into three categories: (1) products where the labeled peptide was absent entirely, replaced with a non-peptide substitute or a different peptide; (2) products where the labeled peptide was present but at substantially different concentration than claimed (typically under-dosed, but occasionally over-dosed); and (3) products containing unlabeled additional compounds, including in some cases active pharmaceutical ingredients not approved for supplement use [2].

The 23% figure is an aggregate across product categories. Pass rates varied significantly by source: products from manufacturers with published third-party testing programs passed at rates above 95%, while products from low-cost online retailers without independent verification failed at rates approaching 50%. This wide distribution is the most useful insight from the survey: average failure rates obscure the reality that buyers have substantial control over their exposure to mislabeling through source selection.

The 23% figure is often repeated in consumer advisories without context about what the failure modes actually mean for research practice. A product where the labeled peptide is absent entirely—a BPC-157-labeled vial containing only bacteriostatic buffer with no peptide—is categorically different from a product where BPC-157 is present at 4.2 mg in a 5 mg vial (within measurement uncertainty for some assays). Both are counted as failures, but the first is fraudulent substitution and the second is quality-control variance.

Breaking down the original 23% by failure type (reported in the published analysis): approximately 8% of products had complete absence or substitution of the labeled peptide; approximately 10% had quantitative mismatch greater than 20% of label claim; and approximately 5% contained unlabeled compounds in addition to the labeled ingredient. The unlabeled-compound category included detections of unapproved drugs (in a small number of cases), undisclosed preservatives, and in several products, unlabeled peptide byproducts from incomplete synthesis [3].

The research implication is that the 77% pass rate applies only to the narrow criterion of label conformance at a single testing time point. Other quality attributes not tested in the survey—endotoxin contamination, heavy metals, residual solvents, microbial contamination, aggregation state, stability under storage—may fail at additional rates on top of the label-claim failures.

Contamination and mislabeling are often conflated but describe different quality failures with different causes and different buyer protections. Mislabeling is a documentation failure: the product exists as claimed on the label but the claim is false. This can arise from fraudulent intent (substituting a cheap compound for an expensive one), quality control failure (incorrect weighing during vialing), or supply chain error (mislabeled drums of bulk material propagating through vialing).

Contamination is an additive failure: the labeled ingredient is present as claimed, but other unwanted substances are also present. Common contaminants in peptide products include bacterial endotoxin (lipopolysaccharide from Gram-negative bacteria, either from manufacturing water or from microbial contamination during synthesis), heavy metals (arsenic, lead, cadmium from starting materials or manufacturing equipment), residual organic solvents (TFA, acetonitrile, DMF from peptide synthesis and purification), and microbial contamination (bacterial or fungal growth, particularly in multi-dose vials after first access) [4].

Both failure modes require testing to detect, but the tests are different. Mislabeling is caught by identity and quantitation assays (HPLC with UV detection against a reference standard, mass spectrometry for molecular weight confirmation). Contamination is caught by specific assays for each category of contaminant (LAL assay for endotoxin, ICP-MS for heavy metals, headspace GC for residual solvents, USP microbiological testing for microbial load). A comprehensive COA addresses both; a minimal COA may address only identity and purity.

Consumer confusion between brand supplement and research-grade peptide contributes to the mislabeling problem. Dietary supplements containing peptides (typically oral collagen peptides, glutamine, or branched-chain peptides) are regulated under DSHEA in the US and must meet label-claim standards and current good manufacturing practice for dietary supplements (21 CFR 111). Research-grade peptides sold as laboratory reagents are regulated as chemicals, not as foods or drugs, and fall under a substantially lighter label-claim framework that does not require the same pre-market quality verification.

A product labeled research peptide not for human consumption can legitimately be sold with minimal quality claims as long as it is not marketed for human use. The same product repackaged and marketed with health claims would trigger FDA drug-regulation requirements. The grey area exists where research-labeled products are sold to end users who intend human self-administration, accepting the research-use-only disclaimer as a legal formality rather than a meaningful compliance document [5].

For legitimate research use, the regulatory framework that should apply is USP/NF standards for pharmaceutical reagents or, at minimum, suppliers that voluntarily adopt research-reagent quality standards (published identity and purity criteria, lot-specific COAs, traceable reference standards). Suppliers that rely solely on the research-use-only disclaimer without substantive quality documentation should not be used for serious research.

Specific mislabeling patterns documented in the 2023 survey and in subsequent independent testing include: (1) Under-dosing, where vials contain substantially less peptide than labeled, driven by cost-cutting in the supply chain; (2) Over-dosing, where vials contain more peptide than labeled, driven by imprecise manual vialing at small scale; (3) Complete substitution, where cheap peptides (glycine, simple dipeptides) replace expensive labeled compounds; (4) Cross-contamination, where traces of other peptides from shared manufacturing equipment appear in the product; and (5) Placebo vialing, where the vial contains only buffer and preservative with no peptide at all [6].

• Under-dosing: less peptide than labeled (most common failure)
• Over-dosing: more peptide than labeled
• Complete substitution with cheap alternatives
• Cross-contamination from shared equipment
• Placebo vialing: buffer only, no peptide

Placebo vialing is the most egregious failure mode and is, fortunately, relatively rare. When it does occur, it is often associated with business failure (a supplier unable to acquire peptide continuing to ship empty vials) or deliberate fraud. Detection requires actual analytical testing; visual inspection and buyer reviews are inadequate because reconstituted solutions appear identical regardless of content.

The legal and regulatory framework governing research chemicals differs fundamentally from that governing drugs or dietary supplements. A product sold as a research reagent with appropriate disclaimers does not require FDA pre-market approval, does not require manufacturer inspection under drug-GMP rules, and does not require label claims to be verified by the regulator. The Federal Trade Commission can pursue deceptive advertising cases, but the threshold for enforcement action is high and the resources limited.

Where the FDA does take action is when research-labeled products cross into drug marketing territory: explicit claims of medical benefit, direct sale to patients, or advertising targeting patient populations. FDA warning letters to peptide sellers in 2023-2025 have cited these boundary crossings rather than the underlying product quality. Enforcement by FDA is thus a necessary but insufficient quality signal: an FDA-warned seller is definitely problematic, but absence of warning does not imply quality [7].

State-level regulation is similarly limited. Most state pharmacy boards have jurisdiction over licensed pharmacies and prescribers but not over research-chemical suppliers. The US Postal Inspection Service has jurisdiction over mail-based fraud but prioritizes cases with clear victim harm and financial loss, which peptide mislabeling may not reach unless physical injury results.

Source selection is the single most impactful variable a researcher can control. Specific indicators of a verified source include: published third-party testing program with lot-by-lot COAs accessible through a batch-verification URL; manufacturer identification (not just reseller identification) with verifiable facility registration; published stability data on the specific peptide under defined storage conditions; customer service capable of discussing analytical methods in technical detail; and pricing consistent with the true cost of quality manufacturing (substantially below-market prices indicate cost-cutting that almost always manifests as quality failure somewhere).

Independent verification databases, such as ChemVerify, aggregate batch test results and vendor track records to help researchers distinguish verified sources from unverified. When starting a new research program or switching sources, commission an independent third-party retest before relying on the source for ongoing supply. The cost of $100-200 per test is trivial compared to the research cost of experiments run on mislabeled material.

Build supplier relationships over time: after confirming quality through independent retest for initial lots, continue spot-testing at 6-12 month intervals to detect supply chain drift. Maintain written communication with the supplier on analytical methods and specifications so that any deviation from expected quality can be escalated with specific evidence.

Buyers of research-grade peptides have limited consumer-protection recourse when quality failures occur. Payment reversibility is often explicitly disclaimed by suppliers (no refunds on opened vials). Civil litigation against offshore manufacturers is impractical for individual buyers. Regulatory agencies have limited jurisdiction over research-chemical transactions. Credit card chargebacks are sometimes possible for clear fraud but are contested by sellers and often unsuccessful [8].

The practical implication is that research buyers must apply consumer-protection principles at the front end through source selection and independent verification, because back-end recourse is largely unavailable. This asymmetry—all risk on the buyer, minimal accountability on the seller—is a defining feature of the research-chemical market and justifies the level of due diligence that this article recommends.

For institutional research programs, purchasing through established laboratory reagent suppliers (Sigma-Aldrich, Tocris, Cayman Chemical, R&D Systems) or through pharmaceutical-grade custom synthesis companies provides substantial additional protection through the contractual and quality-management frameworks those suppliers operate under. Individual researchers working outside institutional procurement channels assume the corresponding additional risk.

Explore detailed chemical profiles and research guides for compounds discussed in this article:

• BPC-157: Complete Research Guide → /learn/bpc-157
• TB-500: Complete Research Guide → /learn/tb-500
• Epithalon: Complete Research Guide → /learn/epithalon

• Read more: Chinese Research Peptides → https://www.chemverify.com/learn/chinese-research-peptides-quality-risks-verification
• Read more: How to Spot Peptide Contamination → https://www.chemverify.com/learn/spot-peptide-contamination-cloudiness-particles
• Read more: Endotoxin Testing for Peptides → https://www.chemverify.com/learn/endotoxin-testing-for-peptides-essential-safety-protocols-for-research